{"hq_id":"hq-c-org-002109","name":"Clotrimazole","context":"human_adult","risk_level":"low","schema":"legacy","note":"Synthesis unavailable: compound lacks vectorizable regulatory classifications. Raw safety data returned.","data":{"risk_level":"low","summary":"Clotrimazole is a first-generation imidazole antifungal available over-the-counter for topical treatment of vulvovaginal candidiasis, tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), and cutaneous candidiasis. Mechanism: CYP51 (lanosterol 14-alpha-demethylase) inhibition, same as other azoles, but delivered topically with minimal systemic absorption (<0.5% from intact skin). Also available as an oral troche for oropharyngeal candidiasis. Excellent safety profile: adverse effects limited to local irritation, burning, and erythema at application site in 1-5% of patients. No significant systemic toxicity or drug interactions with topical use. WHO Essential Medicine. Safe in pregnancy for vaginal use (FDA Category B for vaginal; Category C for oral troches). Available worldwide without prescription for most indications. One of the most widely used antifungal agents globally. Resistance remains uncommon for dermatophytes and most Candida species. Environmental concern: detected in wastewater at low concentrations but ecotoxicological significance is minimal.","source_refs":["aletheia_fungi_batch_2026"]},"meta":{"synthesis_version":"n/a","timestamp":"2026-07-27T02:34:55.434Z"},"_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult"]}